Incretin mimetics include liraglutide and semaglutide (GLP-1RAs), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) which induce approximately 15–24% weight loss in adults with overweight and obesity [128], alongside beneficial impacts on cardiometabolic factors including glycemia, MASLD/MASH and OSA. The gene discussed is GIP; the disease is obesity disorder.